Prademagene zamikeracel is under clinical development by Abeona Therapeutics and currently in Phase III for Epidermolysis Bullosa. According to GlobalData, Phase III drugs for Epidermolysis Bullosa does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Prademagene zamikeracel LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Prademagene zamikeracel overview
Prademagene zamikeracel (EB-101) is under development for the treatment of recessive dystrophic epidermolysis bullosa. The therapeutic candidate is applied topically. It constitutes Col7A1 engineered autologous epidermal sheets delivered using a retroviral vector.
Abeona Therapeutics overview
Abeona Therapeutics (Abeona), formerly PlasmaTech Biopharmaceuticals Inc, is a biopharmaceutical company that develops and delivers gene therapy and plasma-based products for severe life-threatening rare diseases. The company’s lead programs include EB-101, ABO-101 and ABO-102 adeno-associated virus. Abeona develops EB-101 for recessive dystrophic epidermolysis bullosa (RDEB), EB-201 for epidermolysis bullosa (EB), ABO-202 (AAV-CLN1) gene therapy for the treatment of infantile Batten disease (INCL), ABO-201 (AAV-CLN3) gene therapy for Juvenile Batten disease (JNCL) and more. The company has partnerships for the commercialization of its products in the US, European Union, Switzerland, Norway, Iceland, Lichtenstein, Australia, New Zealand, China and South Korea. Abeona is headquartered in New York City, the US.
For a complete picture of Prademagene zamikeracel’s drug-specific PTSR and LoA scores, buy the report here.